Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1992-05-19
1993-09-21
Ivy, C. Warren
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546143, 546144, 546146, 546147, 546149, 546150, 514310, 560 40, 562446, 568442, 568638, 568644, A61K 3147, C07D21716
Patent
active
052469433
ABSTRACT:
This invention relates to novel substituted 1,2,3,4-tetrahydroisoquinolines which are useful in the treatment of vascular restenosis, various disorders of the central nervous system, in the regulation of female reproductive functions, in cognitive enhancement, in atherosclerosis and in treating excessive AVP secretory disorders. Novel intermediates useful in the preparation of the compounds are also disclosed. Methods of using the compounds and pharmaceutical compositions containing them are disclosed.
REFERENCES:
patent: 4812462 (1989-03-01), Blankley
patent: 4925943 (1990-05-01), Kanmacher et al.
patent: 5059608 (1991-10-01), Takasugi et al.
Am. J. Med., 76:4-12 (1984), W. P. Castelli, "Epidemiology of Coronary Heart Disease . . . ".
Hypertension 9:178-187 (1987), G. K. Owens, "Influence of Blood Pressure on Development of Aortic . . . ".
Science 245:186-188 (1989), J. S. Powell et al., "Inhibitors of Angiotensin-Converting . . . ".
Hypertension 18 [Suppl II]:II65-II69 (1991), A. W. Clowes, "Heparin and Cilazapril Together Inhibit . . . .".
ibid, II60-II64, W. Osterrieder et al., "Role of Angiotensin II in Injury-Induced Neointima . . . ".
J. Card Pharmacol., 16(4):S42-S49 (1990), J. W. Powell, "The Proliferative Response to Vascular Injury . . . ".
Hypertension, 18[Supp. II]:II55-II59 (1991), J. Clozel, "Inhibiton of Converting Enzyme and Neointima . . . ".
ibid, :II47-II54, D. Plissonnier et al., "Effect of Converting Enzyme Inhibition . . . ".
ibid, II43-II46, S. Roux, "Cilazapril Inhibits Wall Thickening of Vein Bypass Graft in the Rat".
Clin. Cardiol., 13:VII-43-48 (1990), A. V. Chobanian, "The Effects of ACE Inhibitors and Other . . . ".
J. Card. Pharmacol., 15(5):S65-S72, G. Aberg et al., "Effects of Captopril on Atherosclerosis . . . ".
J. Clin. Invest., 83:1419-1424 (1989), A. Naftilan et al., "Induction of Platelet-derived Growth . . . ".
Biochem. Biophys. Res. Comm., 165(1):196-203 (1989), A. Chiu et al., "Identification of Angiotensin . . . ".
ibid, 172(3):1195-1202 (1990), A. Chiu et al., "[3H]DUP 753, a highly potent and specific . . . ".
Molecular Pharm., 38:370-377 (1990), D. Dudley et al., "Subclasses of Angiotensin II Binding Sites and . . . ".
Am. J. Pathology, 139(6):1291-1296 (1991), M. Prescott et al., "Angiotensin-converting Enzyme Inhibitor . . . ".
Life Sciences, 49:PL-223-PL-228 (1991), R. Kauffman, "Losartan, a Nonpeptide Angiotensin . . . ".
J. Clin. Invest., 88:921-933 (1991) E. Grady et al., "Expression of AT2 Receptors in the Developing . . . ".
Biochem. Biophys. Res. Comm., 179(3):1361-1367 (1991), M. Viswanathan et al., "Changes in Expression . . . ".
Ann. Rev. Physiol., 49:413-435 (1987), M. I. Phillips, "Functions of Angiotensin in the Control . . . ".
Brain Res., 507:341-343 (1990) J. Barnes et al., "Angiotensin II inhibits acetylcholine . . . ".
Pharm. Biochem. & Behavior, 33:573-579 (1989), B. Costall, "The Effects of ACE Inhibitors Captopril . . . ".
Hypertension, 17:425 (1991), Schiavone et al.
Psychosmoatic Medicine 35:143-154 (1973), D. Janowsky et al., "Correlations Betwen Mood, Weight, . . . ".
Biochemical Pharmacology, 42(4):715-719 (1991), P. Andrade-Gordon, "Role of Angiotensin . . . ".
Blankley Clifton J.
Hodges John C.
Klutchko Sylvester
Anderson Elizabeth M.
Ivy C. Warren
Turnipseed James H.
Warner-Lambert & Company
LandOfFree
Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II r does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II r, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II r will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1050016